Karbinal er dosage?

See the DrugPatentWatch profile for Karbinal

What’s “Karbinal” and where does the “ER” fit in?
Karbinal is the brand name for the chemotherapy drug carboplatin. It is given as an intravenous infusion; no approved extended‑release formulation exists. Because it is a chemotherapy agent, the dose is calculated from the patient’s body surface area (BSA) and kidney function, rather than a fixed mg value.

Typical carboplatin dose calculations
The most common method is the Calvert formula:

Dose (mg) = target AUC (mg·min/mL) × (GFR + 15)

* Target AUC – 4 mg·min/mL for most solid tumors, 5 mg·min/mL for some lung cancers, or 3 mg·min/mL for less aggressive regimens.
* GFR – measured or estimated glomerular filtration rate; if unavailable, 15 mL/min is added as a safety margin.
* Example – A patient with a BSA of 1.8 m², GFR 60 mL/min, and a target AUC of 4 receives
4 × (60 + 15) = 300 mg, then divided by BSA (300 mg / 1.8 = 166 mg/m²).

Common infusion schedules
| Indication | Typical AUC | Frequency | Comment |
|------------|-------------|-----------|---------|
| Non‑small‑cell lung cancer | 5 mg·min/mL | 3 weeks | Often combined with docetaxel |
| Ovarian cancer | 4 mg·min/mL | 3 weeks | With paclitaxel |
| Breast cancer (neoadjuvant) | 4 mg·min/mL | 3 weeks | With trastuzumab |

Adjustments for renal function
If GFR < 30 mL/min, the target AUC is reduced or the drug is held. Neutropenia or thrombocytopenia often requires dose reduction.

What about an “ER” product?
There is no Karbinal extended‑release capsule or tablet on the market. All approved uses are intravenous. Because the drug is administered in a single infusion, the “ER” designation does not apply.

Patents and commercial outlook
Carboplatin was patented in the 1980s, and most of those patents have